Nab-paclitaxel as second-line treatment in advanced biliary cancer

被引：0
|
作者：
Unseld, M. [1 ]
Kornek, G. [2 ]
Werner, S. [2 ]
Guenther, S. [2 ]
Christoph, Z.
Gerald, P.
机构：
[1] Med Univ Vienna, Oncol, Vienna, Austria
[2] MUW, Oncol, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31215-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2299
引用
收藏
页码：S431 / S432
页数：2
相关论文
共 50 条
  • [41] Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
    Sawada, Masashi
    Kasuga, Akiyoshi
    Mie, Takafumi
    Furukawa, Takaaki
    Taniguchi, Takanobu
    Fukuda, Koshiro
    Yamada, Yuto
    Takeda, Tsuyoshi
    Kanata, Ryo
    Matsuyama, Masato
    Sasaki, Takashi
    Ozaka, Masato
    Sasahira, Naoki
    BMC CANCER, 2020, 20 (01)
  • [42] Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
    Masashi Sawada
    Akiyoshi Kasuga
    Takafumi Mie
    Takaaki Furukawa
    Takanobu Taniguchi
    Koshiro Fukuda
    Yuto Yamada
    Tsuyoshi Takeda
    Ryo Kanata
    Masato Matsuyama
    Takashi Sasaki
    Masato Ozaka
    Naoki Sasahira
    BMC Cancer, 20
  • [43] Second-line chemotherapy in advanced pancreatic cancer patients before nab-paclitaxel introduction. Retrospective study in Reggio Emilia Clinical Cancer Centre
    Baldi, L.
    Panebianco, M.
    Rossi, P. Giorgi
    Di Felice, E.
    Cassetti, T.
    Sassatelli, R.
    Rondini, E.
    Boni, C.
    Pinto, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Okamoto, Takeshi
    Hamada, Tsuyoshi
    Ishitsuka, Takahiro
    Yamada, Manabu
    Nakagawa, Hiroki
    Furukawa, Takaaki
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    CANCERS, 2023, 15 (02)
  • [45] Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Tober, Nastassja
    Nigro, Maria Concetta
    Mosca, Mirta
    Palloni, Andrea
    Abbati, Francesca
    Frega, Giorgio
    De Lorenzo, Stefania
    Tavolari, Simona
    Brandi, Giovanni
    ANTICANCER RESEARCH, 2020, 40 (06) : 3013 - 3030
  • [46] Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
    Bukhari, Nedal
    Abdalla, Khalda
    Ibnshamsa, Fahad
    Alselwi, Waleed
    Al-Shakir, Shakir
    Alqahtani, Mohammed
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [47] Third -line re -treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel
    Das, A.
    Dean, A.
    McNulty, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
    Sandeep Gedela
    Pritesh Munot
    Arvind Vaidyanathan
    Ritam Joarder
    Deepali Chaugule
    Manali Parulekar
    Chaitali Nashikkar
    Aayushi Ghadi
    Divya Vadodaria
    Mahesh Goel
    Shraddha Patkar
    Sarika Mandavkar
    Anant Ramaswamy
    Prabhat Bhargava
    Sujay Srinivas
    Vikas Ostwal
    Journal of Gastrointestinal Cancer, 2024, 55 : 263 - 269
  • [49] Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP
    Roth, Marc T.
    Goff, Laura W.
    JAMA ONCOLOGY, 2019, 5 (06) : 831 - 832
  • [50] Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers
    Gedela, Sandeep
    Munot, Pritesh
    Vaidyanathan, Arvind
    Joarder, Ritam
    Chaugule, Deepali
    Parulekar, Manali
    Nashikkar, Chaitali
    Ghadi, Aayushi
    Vadodaria, Divya
    Goel, Mahesh
    Patkar, Shraddha
    Mandavkar, Sarika
    Ramaswamy, Anant
    Bhargava, Prabhat
    Srinivas, Sujay
    Ostwal, Vikas
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (01) : 263 - 269
12345